Abstract
Background Codeine is one of the most commonly used opioids worldwide and is available in different formulations, often combined with other simple analgesics. There is a growing concern of the potential harms associated with codeine misuse in the Australian community, and for this reason codeine containing analgesics have been upscheduled in Australia to ‘prescription only medicines’ from February 2018. There is currently limited knowledge on the views of Australian adults experiencing pain symptoms on this codeine restriction, and whether this change has impacted their ability to adequately manage their pain. Objective To investigate the views of adults experiencing pain on the 2018 codeine upscheduling in Australia. Setting Adults experiencing pain symptoms, predominantly recruited from Victoria, Australia. Method A descriptive cross-sectional study was conducted using a pre-tested customised anonymous self-administered questionnaire between January and March 2019. To capture a broad range of demographics, participants were recruited from ten Victorian community pharmacies across metropolitan Melbourne, Australia. Main outcome measure Opinions of Australian adults experiencing pain to targeted questions regarding the 2018 codeine upscheduling, including perceived advantages and disadvantages. Results A total of 120 participants completed the questionnaire. Sixty-two (52%) participants agreed/strongly agreed that codeine was helpful in alleviating pain symptoms before a prescription was required; while 43% of participants felt the codeine restriction has made it more difficult to manage their pain, with 33% unsure. Participants who were in favour of the codeine upscheduling believed that they are now more encouraged to consult healthcare professionals and make better use of the pain management services made available to them in the Australian community; however some now question the value of pharmacists in this context, given that there is now a reduced array of analgesic medicines available at pharmacies without a prescription. Conclusion This study showed there are mixed views, with some participants being unsure or not in favour of the codeine upscheduling, particularly based on qualitative responses. There is also opportunity in this space for healthcare providers to extend beyond standard practice and offer alternative pain management advice and support now that codeine is no longer available in Australian pharmacies without a prescription.
Similar content being viewed by others
References
Hamer AM, Spark MJ, Wood PJ, Roberts E. The upscheduling of combination analgesics containing codeine: the impact on the practice of pharmacists. Res Soc Adm Pharm. 2014;10(4):669–78.
Tobin CL, Dobbin M, McAvoy B. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. Aust N Z J Public Health. 2013;37(5):483–8.
Sansgiry SS, Bhansali AH, Bapat SS, Xu Q. Abuse of over-the-counter medicines: a pharmacist’s perspective. Integr Pharm Res Pract. 2017;6:1–6.
Cairns R, Brown JA, Buckley NA. The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia’s largest poisons centre. Addict. 2016;111(10):1848–53.
Pilgrim JL, Dobbin M, Drummer OH. Fatal misuse of codeine-ibuprofen analgesics in Victoria, Australia. Med J Aust. 2013;199(5):329–31.
Emmerton L. The ‘third class’ of medications: sales and purchasing behavior are associated with pharmacist only and pharmacy medicine classifications in Australia. J Am Pharm Assoc. 2009;49(1):31–7.
Tan ACW, Emmerton L. Non-prescription medicines: current issues in Australian community pharmacy. Int J Pharm Pract. 2009;17(4):207–13.
McCoy J, Bruno R, Nielsen S. Attitudes in Australia on the upscheduling of over-the-counter codeine to a prescription-only medication. Drug Alcohol Rev. 2018;37(2):257–61.
Therapeutic Guidelines Limited. Acute pain: a general approach. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2018 [cited 2019 Jun 5].
Shaheed CA, Maher CG, McLachlan A. Investigating the efficacy and safety of over-the-counter codeine containing combination analgesics for pain and codeine based antitussives. Canberra: Ther Goods Adm; 2016.
Carroll PR, Moles R, Hillman J. Do pharmacists have a role in recommending codeine for pain management? Australian perspectives. Can J Hosp Pharm. 2016;69(6):501–4.
Schug SA, Dobbin MD, Pilgrim JL. Caution with the forthcoming rescheduling of over-the-counter codeine-containing analgesics. Med J Aust. 2018;208(1):51–2.
Van Hout M-C, Norman I. Misuse of non-prescription codeine containing products: recommendations for detection and reduction of risk in community pharmacies. Int J Drug Policy. 2016;27:17–22.
Hopkins RE, Dobbin M, Pilgrim JL. Unintentional mortality associated with paracetamol and codeine preparations, with and without doxylamine, in Australia. Forensic Sci Int. 2018;282:122–6.
Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf. 2016;25:521–38.
Foley M, Carney T, Rich E, Parry C, Van Hout M-C, Deluca P. Medical professionals’ perspectives on prescribed and over-the-counter medicines containing codeine: a cross-sectional study. BMJ Open. 2016;6(7):e011725.
Mishriky J, Stupans I, Chan V. Pharmacists’ views on the upscheduling of codeine-containing analgesics to ‘prescription only’ medicines in Australia. Int J Clin Pharm. 2019;41(2):538–45.
Bresee LC. An introduction to developing surveys for pharmacy practice research. Can J Hosp Pharm. 2014;67(4):286–91.
Hassali M, Saleem F, Farooqui M, Aljadhey H. Strengthening pharmacy practice research: the need for combining both qualitative and quantitative methodology. J Pharm Care Health Syst. 2014;1:1–4.
Briggs AM, Buchbinder R. Back pain: a national health priority area in Australia? Med J Aust. 2009;190(9):499–502.
Walker BF, Muller R, Grant WD. Low back pain in Australian adults. Prevalence and associated disability. J Manip Physiol Ther. 2004;27(4):238–44.
Dutch MJ. Nurofen plus misuse: an emerging cause of perforated gastric ulcer. Med J Aust. 2008;188(1):56–7.
Frei MY, Nielsen S, Dobbin MD, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine–ibuprofen analgesics: a series of 27 cases. Med J Aust. 2010;193(5):294–6.
Ng JL, Morgan DJ, Loh NK, Gan SK, Coleman PL, Ong GS, et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust. 2011;194(6):313–6.
Cairns R, Schaffer AL, Brown JA, Pearson SA, Buckley NA. Codeine use and harms in Australia: evaluating the effects of re-scheduling. Addict. 2020;115(3):451–9. https://doi.org/10.1111/add.14798.
Middleton M, Nielsen S. Changes in Australian prescription opioid use following codeine rescheduling: a retrospective study using pharmaceutical benefits data. Int J Drug Policy. 2019;74:170–3.
Chan V, Tran H. Purchasing over-the-counter medicines from Australian pharmacy: What do the pharmacy customers value and expect? Pharm Pract Granada. 2016;14(3):782–9.
Mishriky J, Stupans I, Chan V. Expanding the role of Australian pharmacists in community pharmacies in chronic pain management—a narrative review. Pharm Pract Granada. 2019;17(1):1410.
Acknowledgements
The authors would like to thank the participating pharmacies and Australian adults who participated in the questionnaire for their valuable insights and comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
There were no external sources of funding for this study.
Conflicts of interest
The authors have no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Mishriky, J., Stupans, I. & Chan, V. The views of Australian adults experiencing pain on the upscheduling of codeine-containing analgesics to ‘prescription only’. Int J Clin Pharm 43, 386–393 (2021). https://doi.org/10.1007/s11096-020-01026-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-020-01026-z